Two-week infusion of muscle-derived differentiation factor (MDF), or human recombinant acidic fibroblast growth factor (aFGF) and/or its muscle-derived activating substance into the striatum of unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rats caused a significant and long lasting (40 days) reduction (48-100%) in amphetamine-induced rotational asymmetry. In parallel with behavioural recovery, striatal tyrosine hydroxylase (TH) activity, dopamine (DA) and dihydroxy-phenylacetic acid (DOPAC) levels recovered in a dose-dependent manner in all treated rats when compared to controls. The greatest increments were observed in rats infused with aFGF and its activator. Increases in biochemical indices were not reflected in trophic changes of the dopamine system; thus, the number of TH-immunoreactive neurones and their striatal innervation were unmodified by treatment with MDF. In contrast with the lesioned brain, infusion of these agents into the intact brain produced no change in nigrostriatal dopamine biochemistry. Our results suggest that dopamine differentiation factors may be important in regulating the production of dopamine in the injured brain and, therefore, may be useful in the treatment of DA imbalances associated with certain neurological disorders such as Parkinson's disease. aFGF, DA, Parkinson's disease, Rotation, 6-OHDA,TH
Introduction
The most salient feature in Parkinson's disease (PD) (Gibb 1988 , Hornykiewicz et al. 1989 , Marsden 1990 ) is the degeneration of melanized dopaminergic neurones in the substantia nigra (SN) (Hirsch et al. 1988) , resulting in a depletion in TH, other catecholamine-related enzymes and DA levels in the striatum (Lloyd et al. 1975 , Nagatsu et al. 1984 , Riederer et al. 1989 . Over the years, a variety of pharmaceutical therapies (L-dopa, deprenyl, etc.) have been used in an attempt to restore transmitter levels to normal (for review see Jankovic & Marsden 1988) . Unfortunately, these treatments have been only transiently effective and are oftentimes accompanied by serious side effects. More recently, transplantation of neural tissue (Freed et al. 1981 , 1985a ,b, 1992 , Backlund et al. 1985 , Dunnett et al. 1985 , 1987 , Hefti et al. 1985 , Olson et al. 1985 , Spencer et al. 1992 , Widner et al. 1992 , Gage et al. 1993 or other genetically modified cells (Fisher et al. 1990 , Horellou et al. 1990 , Kang et al. 1993 has been tried as a means of replacing the transmitter producing cells that are missing in PD. However, both the therapeutic efficacy and the ethical questions posed by these experimental paradigms remain controversial.
Another approach explored in our laboratory has been the discovery of highly specific substances, called differentiation factors, which regulate the expression of neurotransmitter-related genes in development. Our hope is that an understanding of those mechanisms that first direct expression of dopamine-specific genes during differentiation will provide insight into those processes required to modify that expression as required after injury or disease.
Studies from this laboratory initially identified a putative dopamine differentiation factor(s) present in muscle extract and termed muscle-derived differentiation factor(s) (MDF). MDF had the unique ability to induce, in culture, novel transcription of the gene for TH in the phenotypically plastic neurones of the embryonic striatum (Iacovitti et al. 1989 , Iacovitti 1991 . Moreover, studies of cultured dopamine neurones from the SN demonstrated that MDF could also amplify the expression of TH in neurones normally expressing the enzyme (Iacovitti et al. 1992) . We therefore initiated studies to determine the in vivo usefulness of MDF
